Commonwealth Equity Services LLC Reduces Holdings in BioNTech SE (NASDAQ:BNTX)

Commonwealth Equity Services LLC lowered its position in BioNTech SE (NASDAQ:BNTX) by 14.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,696 shares of the company’s stock after selling 442 shares during the period. Commonwealth Equity Services LLC’s holdings in BioNTech were worth $307,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its position in BioNTech by 412.3% during the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after purchasing an additional 33,375 shares during the period. Mirabaud & Cie SA purchased a new stake in shares of BioNTech during the 4th quarter valued at approximately $684,000. Bank of New York Mellon Corp boosted its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after buying an additional 150 shares during the period. Vestcor Inc purchased a new position in BioNTech in the 3rd quarter valued at approximately $784,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in BioNTech during the 4th quarter valued at $1,118,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of analyst reports. Citigroup assumed coverage on BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target for the company. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company. Wells Fargo & Company started coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. HC Wainwright cut their price objective on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Finally, Morgan Stanley decreased their target price on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Trading Down 1.4 %

NASDAQ BNTX opened at $86.82 on Tuesday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $108.15 and its two-hundred day simple moving average is $112.59. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a market capitalization of $20.83 billion, a price-to-earnings ratio of -41.34 and a beta of 1.07.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.90 EPS. Research analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.